• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胆管癌中的表观基因组失调。

Epigenome dysregulation in cholangiocarcinoma.

机构信息

Biotech Research & Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Ole Maaløes Vej 5, 2200 Copenhagen N, Denmark.

Biotech Research & Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Ole Maaløes Vej 5, 2200 Copenhagen N, Denmark.

出版信息

Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1423-1434. doi: 10.1016/j.bbadis.2017.06.014. Epub 2017 Jun 20.

DOI:10.1016/j.bbadis.2017.06.014
PMID:28645654
Abstract

Epigenomics is a fast-evolving field of research that has lately attracted considerable interest, mainly due to the reversibility of epigenetic marks. Clinically, among solid tumors, the field is still limited. In cholangiocarcinoma (CCA) it is well known that the epigenetic landscape is deregulated both during carcinogenesis and disease progression as a consequence of aberrant mechanisms leading to genome instability. In this article, we will briefly review the molecular alterations that have been described in the transformation of normal cholangiocytes into malignant derivatives, focusing on the role of non-coding RNA (ncRNA) interactions, DNA methylation, post-translational modifications (PTMs) of histones and chromatin remodeling complexes.

摘要

表观基因组学是一个快速发展的研究领域,最近引起了相当大的关注,主要是因为表观遗传标记具有可逆性。在临床上,在实体肿瘤中,该领域仍然有限。在胆管癌(CCA)中,众所周知,由于导致基因组不稳定的异常机制,表观遗传景观在癌变和疾病进展过程中都受到了调节。在本文中,我们将简要回顾一下在正常胆管细胞向恶性衍生转化过程中描述的分子改变,重点介绍非编码 RNA(ncRNA)相互作用、DNA 甲基化、组蛋白翻译后修饰(PTMs)和染色质重塑复合物的作用。

相似文献

1
Epigenome dysregulation in cholangiocarcinoma.胆管癌中的表观基因组失调。
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1423-1434. doi: 10.1016/j.bbadis.2017.06.014. Epub 2017 Jun 20.
2
Epigenome Remodeling in Cholangiocarcinoma.胆管癌中的表观基因组重塑
Trends Cancer. 2019 Jun;5(6):335-350. doi: 10.1016/j.trecan.2019.05.002. Epub 2019 Jun 4.
3
Epigenetic regulation in the carcinogenesis of cholangiocarcinoma.胆管癌发生过程中的表观遗传调控
Int J Biochem Cell Biol. 2015 Oct;67:110-4. doi: 10.1016/j.biocel.2015.06.012. Epub 2015 Jun 19.
4
Role of epigenetic alterations in cholangiocarcinoma.表观遗传改变在胆管癌中的作用。
J Hepatobiliary Pancreat Surg. 2006;13(4):274-9. doi: 10.1007/s00534-005-1055-3.
5
The roles of epigenetic regulation in cholangiocarcinogenesis.表观遗传调控在胆管癌发生中的作用。
Biomed Pharmacother. 2023 Oct;166:115290. doi: 10.1016/j.biopha.2023.115290. Epub 2023 Aug 7.
6
Long noncoding RNA ANRIL promotes the malignant progression of cholangiocarcinoma by epigenetically repressing ERRFI1 expression.长链非编码 RNA ANRIL 通过表观遗传抑制 ERRFI1 表达促进胆管癌的恶性进展。
Cancer Sci. 2020 Jul;111(7):2297-2309. doi: 10.1111/cas.14447. Epub 2020 May 30.
7
Involvement of Epigenomic Factors in Bile Duct Cancer.表观遗传因子在胆管癌中的作用。
Semin Liver Dis. 2022 May;42(2):202-211. doi: 10.1055/s-0042-1748188. Epub 2022 Jun 23.
8
Epigenetic alterations associated with cholangiocarcinoma (review).与胆管癌相关的表观遗传改变(综述)
Oncol Rep. 2009 Aug;22(2):227-32.
9
Genetic and epigenetic changes associated with cholangiocarcinoma: from DNA methylation to microRNAs.与胆管癌相关的遗传和表观遗传变化:从DNA甲基化到微小RNA
World J Gastroenterol. 2007 Dec 28;13(48):6465-9. doi: 10.3748/wjg.v13.i48.6465.
10
Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway.胆管癌中 DNA 甲基化的全局改变靶向 Wnt 信号通路。
Hepatology. 2014 Feb;59(2):544-54. doi: 10.1002/hep.26721. Epub 2013 Dec 24.

引用本文的文献

1
Actin-Like Protein 6A as an Oncogene and Therapeutic Target in Cancer.肌动蛋白样蛋白6A作为癌症中的一种癌基因和治疗靶点
Int J Med Sci. 2025 Jun 12;22(12):2906-2918. doi: 10.7150/ijms.113736. eCollection 2025.
2
Mapping the landscape of biliary tract cancer in Europe: challenges and controversies.绘制欧洲胆管癌的全景图:挑战与争议
Lancet Reg Health Eur. 2025 Feb 19;50:101171. doi: 10.1016/j.lanepe.2024.101171. eCollection 2025 Mar.
3
Targeting Glycolytic Reprogramming in Cholangiocarcinoma: A Novel Approach for Metabolic Therapy.
靶向胆管癌中的糖酵解重编程:代谢治疗的新方法
J Inflamm Res. 2024 Nov 25;17:9665-9681. doi: 10.2147/JIR.S497551. eCollection 2024.
4
Genetic, Epigenetic, and Microenvironmental Drivers of Cholangiocarcinoma.胆管癌的遗传、表观遗传和微环境驱动因素
Am J Pathol. 2025 Mar;195(3):362-377. doi: 10.1016/j.ajpath.2024.10.013. Epub 2024 Nov 10.
5
Unveil Intrahepatic Cholangiocarcinoma Heterogeneity through the Lens of Omics and Multi-Omics Approaches.通过组学和多组学方法揭示肝内胆管癌的异质性
Cancers (Basel). 2024 Aug 20;16(16):2889. doi: 10.3390/cancers16162889.
6
Immunomodulatory poly(L-lactic acid) nanofibrous membranes promote diabetic wound healing by inhibiting inflammation, oxidation and bacterial infection.免疫调节性聚(L-乳酸)纳米纤维膜通过抑制炎症、氧化和细菌感染促进糖尿病伤口愈合。
Burns Trauma. 2024 Jun 5;12:tkae009. doi: 10.1093/burnst/tkae009. eCollection 2024.
7
Any Role for Microbiota in Cholangiocarcinoma? A Comprehensive Review.胆管癌中微生物组的作用?全面综述。
Cells. 2023 Jan 19;12(3):370. doi: 10.3390/cells12030370.
8
EZH2 Promotes Cholangiocarcinoma Development and Progression through Histone Methylation and microRNA-Mediated Down-Regulation of Tumor Suppressor Genes.EZH2 通过组蛋白甲基化和 miRNA 介导的肿瘤抑制基因下调促进胆管癌发生和进展。
Am J Pathol. 2022 Dec;192(12):1712-1724. doi: 10.1016/j.ajpath.2022.08.008.
9
Pathological, molecular, and clinical characteristics of cholangiocarcinoma: A comprehensive review.胆管癌的病理、分子及临床特征:综述
World J Gastrointest Oncol. 2022 Mar 15;14(3):607-627. doi: 10.4251/wjgo.v14.i3.607.
10
Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy.胆管癌:遗传和表观遗传因素的作用;检查点抑制剂和免疫疗法的当前及未来治疗方法
Am J Transl Res. 2021 Dec 15;13(12):13246-13260. eCollection 2021.